2025-07-24: DEUSG Virtual

Opening

2

 @Alejandro Lopez Osornio

Welcome & Notification of Recording

Substances Co-Ordination

10

@Krista Lilly 

Workshop/Clinic to support queries from countries currently undergoing reviews in advance of promotion. Policies related to substance submissions during this project.  Substances Co-ordination

Implementation of Routes of Administration for medicines

15

@Mia van Dorp 

Update from New Zealand on Implementation of Routes of Administration

Presentation: 

Editorial advice for PCDs PTs

10

@Alejandro Lopez Osornio @Karen Rees 

Consultation received from members about improving the guidance on this topic

Drug Administration vs Therapy

10

@Nicola Ingram 

Highlight discussion topic

AOB

2

@Alejandro Lopez Osornio 

Prioritize backlog for next steps

Next meeting: August 7th, 2025

Antwerp 2025:

• DEUSG meeting is currently scheduled for Monday October 20th. See timetable: October 2025 - SNOMED International Business Meetings

• SNOMED Expo Programme released. 

Topic Backlog

• Less Granular Clinical Drug

• Elemental Substances (Matt, AUS)

• Substances Co-ordination

  • Step 1: Substances in multiple extensions Batch promotions complete, SI review and authoring underway

  • Step 2: Substances in one extension

  • Step 3: Ongoing Substance Co-ordination (capturing at regulator level)

• Medication Stopped v Medication Discontinued (Karen, SI)

• Medicinal Product promotion co-ordination (Oslo group discussion as linked to substances work + ES)

• Value range of a |Has container type| attribute (Linda, CA)

• Top level children of 373873005 |Pharmaceutical / biologic product| hierarchy - are members using/how are members using? (AUS) 

• Routes of Administration - Implementation Considerations (Mia, NZ)

• Increase range of has active ingredient to include microorganisms and natural products (Guillermo)

• Link between Substances and the organism they come from (Cat dander protein → Cat organism) see PCP-68

Done or in progress:

• Hydration Subsumption 'Option 3' proposed by DEUSG for communication/consultation with MAG and EAG

• Group Input on Patch Strength Representation Briefing note now being implemented

• Dose Form Intended Site v Route of Administration (BEL) Pending implementation use-cases associated with intended site

• Drug extension MRCM attributes (CA, AUS) SI facilitating links with CA and AUS for cross-promotion, next steps: other countries to be invited to add to catalogue